

## REDUCTION OF THE COMPANY'S SHARE CAPITAL

Evry, France, August 4, 2021,

The Combined General Shareholders' Meeting of June 17, 2021 decided in its tenth resolution to reduce the company's share capital.

This reduction was made to increase the company's equity to more than 50% of the company's share capital, as required by the provisions of Article L225-248 of the French Commercial Code.

This reduction in share capital was achieved by reducing the nominal value of the shares from 1 euro to 0,50 euro. The amount of the company's share capital was thus reduced from 6,727,332 euros to 3,363,666 euros, divided into 6,727,332 shares with a par value of 0,50 euros each.

The minutes of the General Meeting are available on the IntegraGen website in the investors' section.

### INTEGRAGEN

IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in DNA sequencing services and genomic data interpretation software. The company runs one of the largest NGS labs in France and operates for research institutes of excellence. As part of OncoDNA group, IntegraGen leverages the power of next generation sequencing with the mission of delivering the promise of precision medicine to patients. IntegraGen has about 50 employees and generated €9 million of revenue in 2020. Based in France, IntegraGen is also present in the United States and is part of the OncoDNA group which works with an international network of 35 distributors. The Group also provides biomarker testing and clinical interpretation tools to guide treatment and monitoring of late stage solid tumors and accelerate the development of new cancer drugs.

IntegraGen is listed on Euronext Growth in Paris (ISIN: FR0010908723 – Mnemo: ALINT – Eligible PEA- PME).

For further information, visit our website [www.integragen.com](http://www.integragen.com) or connect with us on [LinkedIn](#) or [Twitter](#).

#### CONTACTS

**INTEGRAGEN**  
Bernard COURTIEU  
CEO

Pierre FLAMANT  
CFO  
[contact@integragen.com](mailto:contact@integragen.com)  
Tél. : +33 (0)1 60 91 09 00



**NEWCAP**  
**Inverstors and Meda relations**  
Louis-Victor DELOUVRIER  
[integragen@newcap.eu](mailto:integragen@newcap.eu)  
Tél. : +33 (0)1 44 71 98 53